In TKI-naïve NSCLC, the incidence of MET amplification ranges from 2–5%, and reaches 5–20% in NSCLC with resistance to the 1st or 2nd generation of TKIs [2,16,17,18]. Here, MET is linked to non-small cell lung carcinoma.